Cyclerion Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $2.1M | $2.0M | $0 | $297,000 | $3.9M |
| Operating income | -$5.0M | -$3.6M | -$13.0M | -$18.5M | -$55.2M |
| Operating expenses | $7.0M | $5.6M | $13.0M | $18.8M | $59.1M |
| Cash from operations | -$3.3M | -$4.3M | -$21.2M | -$40.6M | -$36.5M |
| Capital expenditure | — | — | — | $0 | $7,000 |
| Free cash flow | — | — | — | -$40.6M | -$36.5M |
| Impairments | — | $0 | $3.3M | $0 | — |
| Total assets | $10.0M | $9.6M | $13.4M | $18.1M | $59.3M |
Shares outstanding 4.3M · Free float 42.8%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.